Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

2

Review clinical trials related to Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

This trial uses blood tests and questionnaires to study how well participants with head and neck cancer that has spread to other places in the body adhere to swallowing exercises to prevent future disease. Using blood tests to study cytokines (proteins related to the immune system) may help doctors learn if certain levels of cytokines affect whether or not side effects occur and if they put participants at risk for future disease. Questionnaires may help doctors learn about the reasons head and neck cancer participants may or may not follow the swallowing exercises that they are asked to perform after receiving radiation treatments.

Participants needed: 471
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 15, 2026Locations: 1
Eligibility criteria

Are dispositioned to receive radiation with curative intent for nasopharyngeal,... [+6]

Have other cancer diagnoses, except non-melanoma skin cancer [+3]

Status: Recruiting

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational HPV blood test. The names of the test and treatments involved in this study are: * NavDx® HPV ctDNA testing (HPV blood test) * Radiation therapy * Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any or all of these agents)

Participants needed: 145
Trial details
Phase: Phase 2Age: 22+Biological sex: AllType: InterventionalSponsor: Jonathan Schoenfeld, MD, MPHUpdated: Jul 30, 2025Locations: 2
Eligibility criteria

Subject must have histologically or cytologically confirmed, stage I, II, or III... [+15]

Patients with AJCC 2017 8th edition stage IVC (metastatic) disease; or patients... [+6]